title: A risk stratification scheme for selection of a glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention based on clinical and angiographic criteria.
authors.affiliation: Cardiac Catheterization Laboratory, Cardiovascular Institute, Mount Sinai Hospital, New York, New York, USA.
authors.forename: A S
authors.initials: AS
authors.lastname: Kini
authors.forename: D
authors.initials: D
authors.lastname: Reich
authors.forename: C A
authors.initials: CA
authors.lastname: Mitre
authors.forename: S K
authors.initials: SK
authors.lastname: Sharma
mesh_terms: D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D017023:Coronary Angiography; D003402:Creatine Kinase / Q000097:blood; D052279:Creatine Kinase, MB Form; D000077542:Eptifibatide; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D007527:Isoenzymes / Q000097:blood; D009203:Myocardial Infarction / Q000175:diagnosis / Q000209:etiology; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011446:Prospective Studies; D012307:Risk Factors; D000077466:Tirofiban; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D007527:Isoenzymes; D010455:Peptides; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form; D000077466:Tirofiban; D000077542:Eptifibatide; D000077284:Abciximab